China’s Medical Enterprise Going Overseas—A Field Visit to Australia 2025 exchange activity is scheduled to launch from March 18 to 24, 2025 in Sydney, Australia.
The major forms of this activity may include medical specialists’ forum, visits to local hospitals, medical enterprises and universities, studying major medical projects, and cooperation-based one-on-one talks with enterprises, aimed at helping participating enterprises gain a quick and informed understanding of market policies, demands, trends as well as competitors’ situation in Australia, so as to find solutions for a series of questions to their concern, including license-out, independent declaration and authorization for entering overseas market, overseas investment & acquisition, supply chain layout, overseas compliance operation, market resources, and so on.
Background
Driven by favorable national policies and individual efforts in recent years, it has become a prevailing trend for medical enterprises in China to seek access to broader market overseas.
In 2023, China’s domestic medical enterprises witnessed a robust growth in license-out businesses, gaining a trade volume of more than 45 billion US dollars. In the first month of 2024 alone, the trade volume hit 9.146 billion US dollars.
The prosperous trade situation is a hard evidence that Chinese innovation medical enterprises have gained recognition from international markets. Therefore, chances are that we can make this year the start of explosive growth for medical enterprises’ license-out.
As a developed country, Australia comes among the top 5 worldwide in per capita income and ranks the world’s second in Human Development Index (HDI). Equipped with global leading medical researchers and health care personnel, as well as state-of-the-art infrastructure, Australi can not only rival the U.S.in this field, but also reach international standards in terms of clinical research capacity.
With abundant foreign investment flowing into it’s pharmaceutical engineering and biotechnology sector, Australia remains a major import country for drugs, despite the fact that it’s export volume has exceeded 5 billion Australian dollars.
Australia possesses a more convenient and optimized rules and regulations over market supervision. Besides this, it’s government offers up to 43.5% of tax refund for clinical research. All these advantages have contributed to the vast foreign investment in Australian’s pharmaceutical engineering and biotechnology sector.
Focus
Overseas Investment & Acquisition/Market Access/A More Diversified Prospects for Future
1.Opening remarks of organizers and distinguished guests:
2.Why we choose Australia for clinical tests how to apply for research tax refund
3.TGA’s requirements for drugs and medical equipment market access & certification management
4.GMP regulations and legal review of listed drugs
5.Welcome Luncheon
6.Solution to Australia biotechnology & clinical tests project
7.Decode Australia medical investment & acquisition
8.Medical study & health care research and cooperation with The University of Sydney
9.Chinese guests: New opportunities & strategies for China’s medical enterprises going overseas
Cooperation projects
- We would like to invite your corporate leader to attend the forum.
Please send us detailed info if there will be a speech or cooperative projects.
- We would like to know if it is possible to organize China’s medical entrepreneurs to visit your corporation.
Email: [email protected]
